Results 1 to 10 of about 20,408 (237)

Safety and effectiveness of triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole in reducing lymphatic filariasis prevalence and clearing circulating filarial antigens in Mombasa, Kenya [PDF]

Infectious Diseases of Poverty
Background In 2018, Kenya introduced triple-drug therapy with ivermectin, diethylcarbamazine, albendazole (IDA) through mass drug administration (MDA) to accelerate the elimination of lymphatic filariasis (LF).
Christabel Khaemba, Sammy M. Njenga, Wyckliff P. Omondi, Elvis Kirui, Margaret Oluka, Anastacia Guantai, Eleni Aklillu   +6 more
doaj   +3 more sources

Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea. [PDF]

PLoS Neglected Tropical Diseases
BackgroundPersons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF ...
Jannet A Tobon Ramos, Tobias Maure, Lenore Carias, Daphne Lew, Charles Goss, Anna Samuel, Livingstone Tavul, Peter U Fischer, Gary J Weil, Moses Laman, Leanne J Robinson, William Pomat, Christopher L King   +12 more
doaj   +3 more sources

Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study [PDF]

Pharmaceuticals, 2021
Preventive chemotherapy with diethylcarbamazine citrate (DEC) and albendazole (ALB) is the core intervention strategy to eliminate lymphatic filariasis (LF).
Christabel Khaemba, Abbie Barry, Wyckliff P. Omondi, Kefa Bota, Sultani Matendechero, Cecilia Wandera, Fred Siyoi, Elvis Kirui, Margaret Oluka, Pamela Nambwa, Parthasarathi Gurumurthy, Sammy M. Njenga, Anastacia Guantai, Eleni Aklillu   +13 more
doaj   +2 more sources

Antifilarial treatment strategies: a systematic review and network meta-analysis [PDF]

BMC Infectious Diseases
Background The World Health Organization (WHO) prescribes mass drug administration (MDA) to eradicate lymphatic filariasis within endemic populations.
Muayad Saud Albadrani, Amr Molla, Hossein M. Elbadawy, Heba M Eltahir, Shyamkumar Sriram, Mekky M Abouzied, Eman Mohamed Sharaf Elsayed   +6 more
doaj   +2 more sources

Probing intermolecular interactions in a diethylcarbamazine citrate salt by fast MAS 1 H solid-state NMR spectroscopy and GIPAW calculations [PDF]

, 2017
Fast magic-angle spinning (MAS) NMR is used to probe intermolecular interactions in a diethylcarbamazine salt, that is widely used as a treatment against adult worms of Wuchereria bancrofti which cause a common disease in tropical countries named ...
Boechat, Nubia, Brown, Steven P., Ellena, Javier, Oliveira, Lyege Magalhaes, Venâncio, Tiago   +4 more
core   +2 more sources

Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch [PDF]

Parasites & Vectors, 2015
Background Elimination of onchocerciasis in Africa is now regarded as an achievable goal in many areas. This makes monitoring changes in infection prevalence a key component of control programmes. Monitoring is currently based on determining the presence
K. Awadzi, Nicholas O. Opoku, Simon K. Attah, Janis K. Lazdins-Helds, Annette C. Kuesel   +4 more
doaj   +2 more sources

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. [PDF]

PLoS Medicine, 2019
BackgroundThe Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medications to hundreds of millions of people annually to treat filarial infections and prevent elephantiasis.
Gary J Weil, Joshua Bogus, Michael Christian, Christine Dubray, Yenny Djuardi, Peter U Fischer, Charles W Goss, Myra Hardy, Purushothaman Jambulingam, Christopher L King, Vijesh Sridhar Kuttiat, Kaliannagounder Krishnamoorthy, Moses Laman, Jean Frantz Lemoine, Katiuscia K O'Brian, Leanne J Robinson, Josaia Samuela, Kenneth B Schechtman, Anita Sircar, Adinarayanan Srividya, Andrew C Steer, Taniawati Supali, Swaminathan Subramanian, DOLF IDA Safety Study Group   +23 more
doaj   +3 more sources

Treatment of loiasis: a review of clinical management recommendations [PDF]

Infectious Diseases of Poverty
Background Loiasis affects more than 20 million residents of endemic regions in Central and West Africa causing chronic and often lifelong disease. Antifilarial treatment options for loiasis include diethylcarbamazine, ivermectin, and albendazole.
Dorothea Ekoka Mbassi, Rike Dreeßen, Rella Zoleko Manego, Saskia Dede Davi, Tamara Nordmann, Johannes Mischlinger, Michael Ramharter   +6 more
doaj   +2 more sources

A low-tech analytical method for diethylcarbamazine citrate in medicated salt. [PDF]

PLoS Neglected Tropical Diseases, 2011
The World Health Organization has called for an effort to eliminate Lymphatic Filariasis (LF) around the world. In regions where the disease is endemic, local production and distribution of medicated salt dosed with diethylcarbamazine (DEC) has been an ...
Abigail Weaver, Patrick Brown, Shannon Huey, Marco Magallon, E Brennan Bollman, Dominique Mares, Thomas G Streit, Marya Lieberman   +7 more
doaj   +3 more sources

Enhancement of Anti-allergic Effect of Diethylcarbamazine Citrate in Asthmatic Mouse Model: Testing of Anti-drug Antibodies and Quercetin

Iranian Journal of Allergy, Asthma and Immunology, 2020
Diethylcarbamazine citrate (DEC) is known as an effective treatment for bronchial asthma because of its ability to reduce eosinophil trafficking to the lung tissue.
Nosibah Abdul-Razek, Al-Mahy M. El-Mallah, Abdelaziz S. A Abuelsaad, Mahmoud Abdel-Latif   +3 more
doaj   +2 more sources